We have developed a proprietary human tissue engineering system that mimics physiological aspects of inflammation.
Using bio-imaging, we can measure:
Recruitment Movement of leukocytes through blood vessel walls
Retention Blockade of leukocytes egress from inflammatory tissue
We can access clinical samples to explore processes in:
Chronic disease modeling
MesenFlow Technologies has developed a platform to meet the demands of modern drug development. It is a bio-imaging technology designed to accelerate the drug development process & provide solutions to problems associated with species cross-reactivity, animal testing & understanding human disease. This has been achieved by using proprietary protocols on primary human cells, allowing the mechanism of action & translational relevance of a drug to be defined very early on in the development process.
MesenFlow Technologies has recently extended this technology for use in cosmetics and nutrition. By using our technology, it is possible to explore the physiological impact of a cosmetic or nutraceutical candidate in the early development phase. Our services are particularly tailored to business environments where animal-free testing is mandatory, and an understanding of impact on human biology is paramount.
Paul Bradfield PhD MBA
Paul has over 20 years experience in translational medicine R&D, in Academia, start-up drug development and large Pharma. Previously he was a Project Leader and Laboratory Head at MerckSerono SA, where he was involved in early drug development, as well as developing translational medicine techniques. He has developed a number of proprietary techniques, and has over 20 publications and patents.
Professor Beat Imhof PhD
Beat is a Senior Professor in the Department of Pathology & Immunology, at the University of Geneva. He held the role of President of the Swiss Society Allergology & Immunology, and has over 170 publications and patents.
+41 22 32 16 961 (office)
+41 79 36 66 291 (mobile)